» Authors » Andre M Willasch

Andre M Willasch

Explore the profile of Andre M Willasch including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 249
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ogishi M, Arias A, Yang R, Han J, Zhang P, Rinchai D, et al.
J Exp Med . 2022 Sep; 219(10). PMID: 36094518
Human cells homozygous for rare loss-of-expression (LOE) TYK2 alleles have impaired, but not abolished, cellular responses to IFN-α/β (underlying viral diseases in the patients) and to IL-12 and IL-23 (underlying...
2.
Bader P, Salzmann-Manrique E, Balduzzi A, Dalle J, Woolfrey A, Bar M, et al.
Blood Adv . 2019 Nov; 3(21):3393-3405. PMID: 31714961
Detection of minimal residual disease (MRD) pre- and post-hematopoietic cell transplantation (HCT) for pediatric acute lymphoblastic leukemia (ALL) has been associated with relapse and poor survival. Published studies have had...
3.
Pichler H, Lawitschka A, Glogova E, Willasch A, von Luettichau I, Lehrnbecher T, et al.
Am J Hematol . 2019 May; 94(8):880-890. PMID: 31095771
Severe infections (SI) significantly impact on non-relapse mortality after hematopoietic stem cell transplantation (HSCT). We assessed 432 children and adolescents with acute lymphoblastic leukemia (ALL) after total body irradiation based...
4.
Wiener L, Hoag J, Pelletier W, Shah N, Shaw B, Pulsipher M, et al.
Bone Marrow Transplant . 2019 Apr; 54(11):1780-1788. PMID: 30971776
Understanding the potential emotional and psychological risks of pediatric sibling HSC donation is an area of research that remains in its infancy. A cross-sectional survey was distributed electronically to directors...
5.
Kuhlen M, Willasch A, Dalle J, Wachowiak J, Yaniv I, Ifversen M, et al.
Br J Haematol . 2017 Dec; 180(1):82-89. PMID: 29193007
Relapse remains the major cause of treatment failure in children with high-risk acute lymphoblastic leukaemia (ALL) undergoing allogeneic haematopoietic stem-cell transplantation (allo-SCT). Prognosis is considered dismal but data on risk...
6.
Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, et al.
J Clin Oncol . 2015 Jan; 33(11):1275-84. PMID: 25605857
Purpose: To elucidate the impact of minimal residual disease (MRD) after allogeneic transplantation, the Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster Stem Cell Transplantation Group (ALL-BFM-SCT) conducted a prospective clinical trial. Patients And...
7.
Rettinger E, Glatthaar A, Abhari B, Oelsner S, Pfirrmann V, Huenecke S, et al.
Front Pediatr . 2014 Aug; 2:75. PMID: 25101252
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment option for high-risk hematological malignancies, and may also be offered to patients with solid malignancies refractory to conventional therapies. In...
8.
Willasch A, Kreyenberg H, Shayegi N, Rettinger E, Meyer V, Zabel M, et al.
Biol Blood Marrow Transplant . 2014 Aug; 20(12):1918-25. PMID: 25087899
Quantitative real-time PCR (qPCR) has been proposed as a highly sensitive method for monitoring hematopoietic chimerism and may serve as a surrogate marker for the detection of minimal residual disease...
9.
Rettinger E, Willasch A, Kreyenberg H, Borkhardt A, Holter W, Kremens B, et al.
Blood . 2011 Sep; 118(20):5681-8. PMID: 21948300
Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). We investigated the...
10.
Ehehalt S, Dietz K, Willasch A, Neu A
Diabetes Care . 2009 Nov; 33(2):338-40. PMID: 19903753
Objective: To predict the frequency of type 1 diabetes in childhood and adolescence (<15 years of age) in Germany for the next 20 years. Research Design And Methods: Data on...